Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Corbus Pharmaceuticals Holding

Healthcare US CRBP

8.55USD
0.09(1.06%)

Last update at 2026-06-24T15:56:00Z

Day Range

8.328.71
LowHigh

52 Week Range

6.1020.56
LowHigh

Fundamentals

  • Previous Close 8.46
  • Market Cap182.60M
  • Volume106323
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-85.07700M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -70.09500M
  • Diluted EPS TTM-5.9

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -78.53700M -40.20900M -44.60332M -42.34690M -45.64043M
Minority interest - - - - -
Net income -78.53700M -40.20900M -44.60332M -55.83319M -45.55259M
Selling general administrative 15.21M 16.50M 13.91M 18.70M 20.43M
Selling and marketing expenses - - 13896.37M - -
Gross profit -0.23300M -0.60000M -0.64100M -1.48785M -0.75753M
Reconciled depreciation 0.23M 0.59M 1.40M 1.49M 1.64M
Ebit -85.31000M -38.33700M -45.07730M -39.83544M -55.98902M
Ebitda -85.07700M -37.73700M -44.43630M -29.50485M -56.26812M
Depreciation and amortization 0.23M 0.60M 0.64M 10.33M -0.27909M
Non operating income net other - - - - -
Operating income -85.31000M -48.72100M -45.07730M -39.83544M -55.98902M
Other operating expenses 85.31M 48.72M 45.08M 34.84M 56.87M
Interest expense 0.00000M 1.87M 2.92M 2.13M 1830.49M
Tax provision - - - - -
Interest income 5.53M 6.31M - - -
Net interest income 5.53M 4.44M -2.85792M -2.13209M -1.83049M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - 13.49M -0.08784M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.88M
Total operating expenses 85.31M 48.12M 44.44M 34.84M 56.87M
Cost of revenue 0.23M 0.60M 0.64M 1.49M 1.64M
Total other income expense net 6.77M 8.51M 0.47M -2.51146M 10.35M
Discontinued operations - - - - -
Net income from continuing ops -78.53700M -40.20900M -47.46097M -42.34690M -45.64043M
Net income applicable to common shares - - - -42.34690M -45.64043M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 168.19M 155.88M 28.27M 66.31M 107.73M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.51M 3.91M 2.45M 0.79M 2.37M
Total liab 20.69M 13.45M 35.18M 33.32M 38.62M
Total stockholder equity 147.50M 142.43M -6.90472M 32.99M 69.11M
Deferred long term liab - - - - -
Other current liab 16.84M 5.43M 11.07M 6.04M 0.13M
Common stock 0.00200M 0.00100M 0.00044M 0.00042M 0.01M
Capital stock 0.00200M 0.00100M 0.00044M 0.00042M 0.01M
Retained earnings -555.43000M -476.89300M -436.68398M -392.08067M -349.73376M
Other liab - - - 0.02M 0.02M
Good will - - - - -
Other assets - - 0.00000M 0.63M 0.52M
Cash 28.49M 17.20M 13.92M 17.00M 25.01M
Cash and equivalents - - - - -
Total current liabilities 20.69M 11.82M 31.89M 12.64M 17.01M
Current deferred revenue - - - - 10.09M
Net debt -26.85900M -13.95900M 6.97M 8.09M 1.58M
Short term debt 1.63M 1.61M 17.65M 4.43M 5.00M
Short long term debt - - 16.21M 3.15M 3.86M
Short long term debt total 1.63M 3.24M 20.88M 25.09M 26.59M
Other stockholder equity 702.98M 619.28M 429.78M 425.20M 418.89M
Property plant equipment - - - 5.50M 7.00M
Total current assets 166.95M 152.98M 23.55M 60.18M 100.20M
Long term investments - - - - -
Net tangible assets - - - 32.99M 69.11M
Short term investments 134.78M 131.86M 7.18M 42.19M 72.64M
Net receivables 1.50M - - - -
Long term debt - - - 15.98M 15.64M
Inventory - - - - -
Accounts payable 2.21M 4.79M 3.18M 2.17M 1.78M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.05300M 0.04M -0.00156M -0.12609M -0.06245M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.39M 0.21M 0.63M 0.52M
Deferred long term asset charges - - - - -
Non current assets total 1.24M 2.90M 4.73M 6.13M 7.53M
Capital lease obligations 1.63M 3.24M 4.68M 5.96M 7.09M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -1.63400M -121.31000M 37.03M 30.07M -73.38625M
Change to liabilities - - - -0.25683M -5.95630M
Total cashflows from investing activities -1.64100M -121.31000M - 30.07M -73.41652M
Net borrowings 0.00000M -15.48000M - -0.53361M 0.06M
Total cash from financing activities 77.43M 166.58M -2.82052M -0.53361M 60.82M
Change to operating activities - - - -3.76668M -11.35847M
Net income -78.53700M -40.20900M -44.60332M -42.34690M -45.64043M
Change in cash 11.29M 3.47M -3.27903M -8.00392M -60.77681M
Begin period cash flow 17.87M 14.39M 17.20M 25.68M 86.45M
End period cash flow 29.16M 17.87M 13.92M 17.67M 25.68M
Total cash from operating activities -64.49100M -41.79400M -36.10047M -37.54444M -48.18370M
Issuance of capital stock 77.43M 182.06M 0.24M 0.04M 62.59M
Depreciation -1.13300M -2.73900M 0.64M 1.49M 1.64M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -1.61830M
Change to account receivables - - - - 1.62M
Sale purchase of stock - - - - -
Other cashflows from financing activities 77.43M 166.58M -0.00000M 1.83M -73.41652M
Change to netincome - - - 6.60M 10.81M
Capital expenditures 0.00700M 0.00000M 0.00000M 0.01M 0.05M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 9.12M -5.57600M 4.09M -4.02351M -15.69647M
Stock based compensation 6.29M 6.14M 3.47M 5.72M 9.48M
Other non cash items -0.22900M 0.58M 1028.58M 1.62M 0.95M
Free cash flow -64.49800M -41.79400M -36.10047M -37.55788M -48.23787M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CRBP
Corbus Pharmaceuticals Holding		 0.09 1.06% 8.55 - - 169.88 1.28 4531.61 0.17
NVO
Novo Nordisk A/S		 0.09 0.19% 47.51 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 46.84 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 7.91 1.69% 476.32 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 3.79 0.61% 621.82 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

Corbus Pharmaceuticals Holding

500 River Ridge Drive, Norwood, MA, United States, 02062

Key Executives

Name Title Year Born
Dr. Yuval Cohen Ph.D. CEO & Director 1975
Mr. Sean F. Moran CPA, M.B.A., CPA, MBA Chief Financial Officer 1958
Mr. Craig Stuart Millian M.B.A. Chief Operating Officer 1969
Dr. Rachael Brake Ph.D. Chief Scientific Officer 1972
Ted Jenkins Sr. Director of Investor Relations & Corp. Communications NA
Ms. Lindsey Smith Head of Corp. Communications & Patient Advocacy NA
Ms. Christina Bertsch Head of HR NA
Scott Constantine Sr. Director & Head of Clinical Operations NA
Mr. Sean F. Moran CPA, M.B.A. Chief Financial Officer 1958
Ms. Lindsey Smith Head of Corporate Communications & Patient Advocacy NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.